Psoriatic Arthritis Therapeutics - Global Strategic Business Report

The global market for Psoriatic Arthritis Therapeutics is estimated at US$10.6 Billion in 2023 and is projected to reach US$20.5 Billion by 2030, growing at a CAGR of 9.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the psoriatic arthritis therapeutics market is driven by several factors, including the increasing prevalence of the disease and a heightened awareness and diagnosis rate among healthcare professionals. Advancements in biotechnology and pharmaceutical research have led to the development of new and more effective treatments, expanding the range of therapeutic options available. The rising demand for biologics and targeted therapies, driven by their efficacy and relatively favorable side effect profiles, significantly contributes to market growth. Moreover, patient behavior is shifting towards seeking more advanced and specialized treatments, supported by greater access to healthcare information and improved healthcare infrastructure globally. Economic factors, such as increased healthcare expenditure and insurance coverage for chronic diseases, further support market expansion. Additionally, ongoing clinical trials and research into novel therapeutic targets promise to introduce new and improved treatments, ensuring sustained growth and innovation in the psoriatic arthritis therapeutics market. These factors collectively foster an environment where continuous advancements are made, aiming to enhance patient outcomes and quality of life for those suffering from PsA.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) segment, which is expected to reach US$6.6 Billion by 2030 with a CAGR of a 9.3%. The Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) segment is also set to grow at 9.3% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $2.9 Billion in 2023, and China, forecasted to grow at an impressive 16.7% CAGR to reach $5.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Psoriatic Arthritis Therapeutics Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Psoriatic Arthritis Therapeutics Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Psoriatic Arthritis Therapeutics Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as AbbVie Inc, Aclaris Therapeutics, Inc., Amgen, Inc., and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 36 Featured):

• AbbVie Inc
• Aclaris Therapeutics, Inc.
• Amgen, Inc.
• Bristol-Myers Squibb Co
• Coherus BioSciences, Inc.
• Eli Lilly and Company
• Fresenius Kabi USA
• GSK Plc
• Johnson & Johnson Services, Inc.
• Novartis Pharmaceuticals Corporation
• Pfizer Inc.
• SANOFI
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• UCB S.A.;